Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumors × Tiragolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 7 Small Cell Lung Carcinoma 3 Squamous Cell Carcinoma of Head and Neck 2 Esophageal Neoplasms 2 Carcinoma, Hepatocellular 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumors 1 Rectal Neoplasms 1 Pancreatic Adenocarcinoma 1 PD-L1-selected Solid Tumors 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Advanced Liver Cancers 1

Interventions

Paclitaxel 11 atezolizumab 9 Gemcitabine 9 pembrolizumab 8 Carboplatin 6 Irinotecan 5 Injections 5 Docetaxel 5 Cetuximab 5 navitoclax 4 Leucovorin 4 Fluorouracil 4 olaparib 3 Oxaliplatin 3 Nivolumab 3 Bevacizumab 3 zolbetuximab 2 tocilizumab 2 tivozanib 2 tislelizumab 2 spartalizumab 2 ridaforolimus 2 plocabulin 2 liposomal doxorubicin 2 linifanib 2 lenvatinib 2 ipatasertib 2 envafolimab 2 cobimetinib 2 brigimadlin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06331598 2024-12-24

IMperator

Hoffmann-La Roche

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡